← Back to Screener
Bolt Biotherapeutics, Inc. Common Stock (BOLT)
Price$5.15
Favorite Metrics
Price vs S&P 500 (26W)-18.10%
Price vs S&P 500 (4W)9.44%
Market Capitalization$9.90M
All Metrics
Book Value / Share (Quarterly)$13.80
P/TBV (Annual)0.20x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.33%
Cash Flow / Share (Quarterly)$-20.79
Price vs S&P 500 (YTD)-9.75%
Net Profit Margin (TTM)-433.74%
EPS (TTM)$-17.79
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-17.79
Revenue Growth (5Y)101.79%
EPS (Annual)$-17.85
ROI (Annual)-125.92%
Net Profit Margin (5Y Avg)-2299.04%
Cash / Share (Quarterly)$14.32
Revenue Growth QoQ (YoY)90.10%
ROA (Last FY)-58.81%
Revenue Growth TTM (YoY)0.07%
EBITD / Share (TTM)$-18.49
ROE (5Y Avg)-77.69%
Operating Margin (TTM)-469.30%
Cash Flow / Share (Annual)$-20.79
P/B Ratio0.37x
P/B Ratio (Quarterly)0.40x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-0.23x
ROA (TTM)-47.15%
EPS Incl Extra (Annual)$-17.85
Current Ratio (Annual)3.59x
Quick Ratio (Quarterly)3.40x
3-Month Avg Trading Volume0.03M
52-Week Price Return-26.43%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.38
P/S Ratio (Annual)1.29x
Asset Turnover (Annual)0.14x
52-Week High$9.25
Operating Margin (5Y Avg)-2253.29%
EPS Excl Extra (Annual)$-17.85
CapEx CAGR (5Y)-53.35%
26-Week Price Return-11.21%
Quick Ratio (Annual)3.40x
13-Week Price Return-26.22%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.59x
Enterprise Value$-1.807
Revenue / Share Growth (5Y)265.60%
Asset Turnover (TTM)0.11x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-433.74%
Cash / Share (Annual)$14.32
3-Month Return Std Dev87.27%
Net Income / Employee (TTM)$-1
ROE (Last FY)-125.92%
EPS Basic Excl Extra (Annual)$-17.85
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-17.79
ROI (TTM)-92.55%
P/S Ratio (TTM)1.29x
Pretax Margin (5Y Avg)-2299.04%
Revenue / Share (Annual)$4.12
Tangible BV / Share (Annual)$4.54
Price vs S&P 500 (52W)-61.06%
Year-to-Date Return-5.82%
5-Day Price Return8.65%
EPS Normalized (Annual)$-17.85
ROA (5Y Avg)-47.24%
Net Profit Margin (Annual)-433.74%
Month-to-Date Return27.48%
Cash Flow / Share (TTM)$-1.84
EBITD / Share (Annual)$-18.49
Operating Margin (Annual)-469.30%
ROI (5Y Avg)-77.69%
EPS Basic Excl Extra (TTM)$-17.79
P/TBV (Quarterly)0.27x
P/B Ratio (Annual)0.40x
Pretax Margin (TTM)-433.74%
Book Value / Share (Annual)$13.80
Price vs S&P 500 (13W)-28.60%
Beta1.15x
Revenue / Share (TTM)$4.46
ROE (TTM)-92.55%
52-Week Low$3.91
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.82
3.82
3.82
3.90
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BOLTBolt Biotherapeutics, Inc. Common Stock | 1.29x | 0.07% | — | — | $5.15 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing tumor-targeted therapies that activate both innate and adaptive immune responses. The company's proprietary Boltbody ISAC platform combines tumor-targeting antibodies with immune-stimulating payloads, leveraging deep expertise in myeloid biology. Its pipeline includes three candidates: BDC-1001, BDC-3042, and a next-generation ISAC therapeutic.